Kindex Therapeutics LLC is categorized under Commercial Biotechnical Research in Seattle, WA and active since 2009.
Kindex Therapeutics LLC was established in 2009, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 4461910 by the NAICS.
If you are seeking more information, feel free to contact Jeffrey Bland at the company’s branch by writing to 800 5th Avenue # 4100, Seattle, Washington WA 98104 or by phoning (206) 447-1455. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Kindex Therapeutics LLC |
| Contact Person: | Jeffrey Bland |
| Address: | 800 5th Avenue # 4100, Seattle, Washington 98104 |
| Phone Number: | (206) 447-1455 |
| Website Address: | kindextherapeutics.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2009 |
| Location Type: | Branch |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 4461910 |
| Share This Business: |
Kindex Therapeutics LLC was started in 2009 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 4461910. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jeffrey Bland for inquiries that concern Kindex Therapeutics LLC by calling the company number (206) 447-1455, as your correspondence is most welcome. Additionally, the physical location of the branch of Kindex Therapeutics LLC can be found at the coordinates 47.605171,-122.330444 as well as the street address 800 5th Avenue # 4100 in Seattle, Washington 98104.
For its online presence, you may visit Kindex Therapeutics LLC’s website at kindextherapeutics.com and engage with its social media outlets through on Twitter and on Facebook.